{"filing":{"accession_number":"0001193125-26-356146","cik":"0001226616","ticker":"MNOV","company_name":"MEDICINOVA INC","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-17","primary_document":"d407050d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1226616/000119312526356146/d407050d8k.htm"},"events":[{"id":28392,"run_id":25968,"accession_number":"0001193125-26-356146","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The disclosure centers on new Executive Employment Agreements entered into on August 17, 2026 with Dr. Yuichi Iwaki (President and CEO) and Dr. Kazuko Matsuda (Chief Medical Officer). The filing details compensatory arrangements including base salaries ($690,246 for Dr. Iwaki; $540,143 for Dr. Matsuda), annual incentive bonuses (55% and 40% of base salary respectively), severance protection terms, equity acceleration provisions, and change-of-control benefits. These are material modifications to executive compensation and severance arrangements that would affect investor assessment of the company's obligations and executive retention.","company_name":"MEDICINOVA INC","ticker":"MNOV","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30325,"accession_number":"0001193125-26-356146","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on new Executive Employment Agreements entered into on August 17, 2026 with Dr. Yuichi Iwaki (President and CEO) and Dr. Kazuko Matsuda (Chief Medical Officer). The filing details compensatory arrangements including base salaries ($690,246 for Dr. Iwaki; $540,143 for Dr. Matsuda), annual incentive bonuses (55% and 40% of base salary respectively), severance protection terms, equity acceleration provisions, and change-of-control benefits. These are material modifications to executive compensation and severance arrangements that would affect investor assessment of the company's obligations and executive retention.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:30:46.148534+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30325,"accession_number":"0001193125-26-356146","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on new Executive Employment Agreements entered into on August 17, 2026 with Dr. Yuichi Iwaki (President and CEO) and Dr. Kazuko Matsuda (Chief Medical Officer). The filing details compensatory arrangements including base salaries ($690,246 for Dr. Iwaki; $540,143 for Dr. Matsuda), annual incentive bonuses (55% and 40% of base salary respectively), severance protection terms, equity acceleration provisions, and change-of-control benefits. These are material modifications to executive compensation and severance arrangements that would affect investor assessment of the company's obligations and executive retention.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:30:46.148534+00:00","company_name":"MEDICINOVA INC","ticker":"MNOV","filing_date":"2026-08-19"}]}